Search research articles
Contact Us
Filters
Showing results (1-10 of 43) with videos related to
Page
of 5
Sort By:
The Lancet. Haematology
|
May 15, 2023
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia
Emily Curran
The Lancet. Haematology
|
July 3, 2025
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia
Emily Curran
Issue Brief (Commonwealth Fund)
|
July 28, 2016
Factors Affecting Health Insurance Enrollment Through the State Marketplaces: Observations on the ACA's Third Open Enrollment Period
Justin Giovannelli, Emily Curran
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 24, 2020
To Transplant or Not? Weighing the Risks of Blinatumomab Prior to Hematopoietic Stem Cell Transplant in Acute Lymphoblastic Leukemia
Punita Grover, Emily Curran
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
Challenges to successful outcomes in AYAs with ALL and potential solutions
Annabelle Anandappa, Emily Curran
Seminars in Hematology
|
December 1, 2020
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease
Emily Curran, Maureen O'Brien
Seminars in Hematology
|
December 1, 2020
Editorial
Emily Curran, Wendy Stock
Issue Brief (Commonwealth Fund)
|
February 10, 2017
Efforts to Support Consumer Enrollment Decisions Using Total Cost Estimators: Lessons from the Affordable Care Act’s Marketplaces
Justin Giovannelli, Emily Curran
Blood
|
February 24, 2019
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL
Emily Curran, Wendy Stock
Blood Advances
|
July 1, 2026
Bridging two worlds: harmonizing pediatric and adult ALL
Daniel Lichtenstein, Emily Curran
Page
of 5
Search research articles
Search
Showing results (1-10 of 43) with videos related to
Sort By:
Page
of 5
The Lancet. Haematology
|
May 15, 2023
Balancing toxicity and effectiveness in older adults with B-cell acute lymphocytic leukaemia
Emily Curran
The Lancet. Haematology
|
July 3, 2025
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia
Emily Curran
Issue Brief (Commonwealth Fund)
|
July 28, 2016
Factors Affecting Health Insurance Enrollment Through the State Marketplaces: Observations on the ACA's Third Open Enrollment Period
Justin Giovannelli, Emily Curran
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 24, 2020
To Transplant or Not? Weighing the Risks of Blinatumomab Prior to Hematopoietic Stem Cell Transplant in Acute Lymphoblastic Leukemia
Punita Grover, Emily Curran
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
Challenges to successful outcomes in AYAs with ALL and potential solutions
Annabelle Anandappa, Emily Curran
Seminars in Hematology
|
December 1, 2020
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease
Emily Curran, Maureen O'Brien
Seminars in Hematology
|
December 1, 2020
Editorial
Emily Curran, Wendy Stock
Issue Brief (Commonwealth Fund)
|
February 10, 2017
Efforts to Support Consumer Enrollment Decisions Using Total Cost Estimators: Lessons from the Affordable Care Act’s Marketplaces
Justin Giovannelli, Emily Curran
Blood
|
February 24, 2019
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL
Emily Curran, Wendy Stock
Blood Advances
|
July 1, 2026
Bridging two worlds: harmonizing pediatric and adult ALL
Daniel Lichtenstein, Emily Curran
Page
of 5